Beta-thalassemia
Open accessThe DOI matches its Crossref record; 4 of the 89 references it cites were found in a registry or an index, and 85 are not checked yet.
Abstract
Beta-thalassemia is caused by the reduced (beta) or absent (beta) synthesis of the beta globin chains of the hemoglobin tetramer. Three clinical and hematological conditions of increasing severity are recognized, i.e., the beta-thalassemia carrier state, thalassemia intermedia, and thalassemia major. The beta-thalassemia carrier state, which results from heterozygosity for beta-thalassemia, is clinically asymptomatic and is defined by specific hematological features. Thalassemia major is a severe transfusion-dependent anemia. Thalassemia intermedia comprehend a clinically and genotypically very heterogeneous group of thalassemia-like disorders, ranging in severity from the asymptomatic carrier state to the severe transfusion-dependent type. The clinical severity of beta-thalassemia is related to the extent of imbalance between the alpha and nonalpha globin chains. The beta globin (HBB) gene maps in the short arm of chromosome 11, in a region containing also the delta globin gene, the embryonic epsilon gene, the fetal A-gamma and G-gamma genes, and a pseudogene (psiB1). Beta-thalassemias are heterogeneous at the molecular level. More than 200 disease-causing mutations have been so far identified. The majority of mutations are single nucleotide substitutions, deletions, or insertions of oligonucleotides leading to frameshift. Rarely, beta-thalassemia results from gross gene deletion. In addition to the variation of the phenotype resulting from allelic heterogeneity at the beta globin locus, the phenotype of beta-thalassemia could also be modified by the action of genetic factors mapping outside the globin gene cluster and not influencing the fetal hemoglobin. Among these factors, the ones best delineated so far are those affecting bilirubin, iron, and bone metabolisms. Because of the high carrier rate for HBB mutations in certain populations and the availability of genetic counseling and prenatal diagnosis, population screening is ongoing in several at-risk populations in the Mediterranean. Population screening associated with genetic counseling was extremely useful by allowing couples at risk to make informed decision on their reproductive choices. Clinical management of thalassemia major consists in regular long-life red blood cell transfusions and iron chelation therapy to remove iron introduced in excess with transfusions. At present, the only definitive cure is bone marrow transplantation. Therapies under investigation are the induction of fetal hemoglobin with pharmacologic compounds and stem cell gene therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803
In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state
Wernig, M., Meissner, A., Foreman, R., Brambrink, T., Ku, M., Hochedlinger, K., Bernstein, B. E., & Jaenisch, R. (2007) · Nature · doi:10.1038/nature05944 · Cited by 2,676
Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload
Anderson, L. (2001) · European Heart Journal · doi:10.1053/euhj.2001.2822 · Cited by 1,682
Common West African HLA antigens are associated with protection from severe malaria
Hill, A. V. S., Allsopp, C. E. M., Kwiatkowski, D., Anstey, N. M., Twumasi, P., Rowe, P. A., Bennett, S., Brewster, D., McMichael, A. J., & Greenwood, B. M. (1991) · Nature · doi:10.1038/352595a0 · Cited by 1,552
Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation
Ganz, T. (2003) · Blood · doi:10.1182/blood-2003-03-0672 · Cited by 1,544
Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin
Hanna, J., Wernig, M., Markoulaki, S., Sun, C.-W., Meissner, A., Cassady, J. P., Beard, C., Brambrink, T., Wu, L.-C., Townes, T. M., et al. (2007) · Science · doi:10.1126/science.1152092 · Cited by 1,202
Variation in the TNF-α promoter region associated with susceptibility to cerebral malaria
McGuire, W., Hill, A. V. S., Allsopp, C. E. M., Greenwood, B. M., & Kwiatkowski, D. (1994) · Nature · doi:10.1038/371508a0 · Cited by 1,169
Rund, D., & Rachmilewitz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050436 · Cited by 939
Human Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-Specific Repressor BCL11A
Sankaran, V. G., Menne, T. F., Xu, J., Akie, T. E., Lettre, G., Van Handel, B., Mikkola, H. K. A., Hirschhorn, J. N., Cantor, A. B., & Orkin, S. H. (2008) · Science · doi:10.1126/science.1165409 · Cited by 919
Research works printed but not linked: 5
- Wheatherall DJ, Clegg JB. The thalassemia syndromes. 4th ed. Oxford, England: Blackwell Science Ltd, 2001.
- Weatherall DJ, Clegg JB, Higgs DR, Wood WG. The hemoglobinopathies. In: Scriver CR, Beaudet Al, Sly WS, Valle D, Vogelstein B, editors. The metabolic and molecular bases of inherited disease (OMMBID). Chapter 101. New York, NY: McGraw-Hill, 2002. Available at: www.ommbid.com. Accessed December 31, 2007.
- Rees, 1998, Genetic influenes on bone disease in thalassemia, Blood, 92, S532a
- Dresner Pollak, 2000, Bone mineral metabolism in adults with beta thalassemia major and intermedia, Br J Haematol, 111, 902
- Galanello, 1990, Deletion delta-thalassemia: the 7.2 kb deletion of Corfu delta beta-thalassemia in a non-beta-thalassemia chromosome, Blood, 15, 75:11747
Cited by
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y.-S., Domm, J., Eustace, B. K., Foell, J., de la Fuente, J., Grupp, S., Handgretinger, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2031054 · Cited by 1,962
RNA therapeutics: beyond RNA interference and antisense oligonucleotides
Kole, R., Krainer, A. R., & Altman, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3625 · Cited by 1,152
CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes
Liang, P., Xu, Y., Zhang, X., Ding, C., Huang, R., Zhang, Z., Lv, J., Xie, X., Chen, Y., Li, Y., et al. (2015) · Protein & Cell · doi:10.1007/s13238-015-0153-5 · Cited by 1,135
Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia
Thompson, A. A., Walters, M. C., Kwiatkowski, J., Rasko, J. E. J., Ribeil, J.-A., Hongeng, S., Magrin, E., Schiller, G. J., Payen, E., Semeraro, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705342 · Cited by 684
Cornerstones of CRISPR–Cas in drug discovery and therapy
Fellmann, C., Gowen, B. G., Lin, P.-C., Doudna, J. A., & Corn, J. E. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.238 · Cited by 443
An APOBEC3A-Cas9 base editor with minimized bystander and off-target activities
Gehrke, J. M., Cervantes, O., Clement, M. K., Wu, Y., Zeng, J., Bauer, D. E., Pinello, L., & Joung, J. K. (2018) · Nature Biotechnology · doi:10.1038/nbt.4199 · Cited by 438
Sidore, C., Busonero, F., Maschio, A., Porcu, E., Naitza, S., Zoledziewska, M., Mulas, A., Pistis, G., Steri, M., Danjou, F., et al. (2015) · Nature Genetics · doi:10.1038/ng.3368 · Cited by 377
Kell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361
Early Neolithic genomes from the eastern Fertile Crescent
Broushaki, F., Thomas, M. G., Link, V., López, S., van Dorp, L., Kirsanow, K., Hofmanová, Z., Diekmann, Y., Cassidy, L. M., Díez-del-Molino, D., et al. (2016) · Science · doi:10.1126/science.aaf7943 · Cited by 288
CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases
Sharma, G., Sharma, A. R., Bhattacharya, M., Lee, S.-S., & Chakraborty, C. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.028 · Cited by 283
Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
Locatelli, F., Lang, P., Wall, D., Meisel, R., Corbacioglu, S., Li, A. M., de la Fuente, J., Shah, A. J., Carpenter, B., Kwiatkowski, J. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309673 · Cited by 253
RNA Splicing and Disease: Animal Models to Therapies
Montes, M., Sanford, B. L., Comiskey, D. F., & Chandler, D. S. (2019) · Trends in Genetics · doi:10.1016/j.tig.2018.10.002 · Cited by 219
Correction of β-thalassemia mutant by base editor in human embryos
Liang, P., Ding, C., Sun, H., Xie, X., Xu, Y., Zhang, X., Sun, Y., Xiong, Y., Ma, W., Liu, Y., et al. (2017) · Protein & Cell · doi:10.1007/s13238-017-0475-6 · Cited by 216
Optimal management of β thalassaemia intermedia
Taher, A. T., Musallam, K. M., Cappellini, M. D., & Weatherall, D. J. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08486.x · Cited by 207
Ginzburg, Y., & Rivella, S. (2011) · Blood · doi:10.1182/blood-2011-03-283614 · Cited by 201
Fu, B., Liao, J., Chen, S., Li, W., Wang, Q., Hu, J., Yang, F., Hsiao, S., Jiang, Y., Wang, L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01906-z · Cited by 181
Antagonistic pleiotropy as a widespread mechanism for the maintenance of polymorphic disease alleles
Carter, A. J., & Nguyen, A. Q. (2011) · BMC Medical Genetics · doi:10.1186/1471-2350-12-160 · Cited by 172
Complications of thalassemia major and their treatment
Borgna-Pignatti, C., & Gamberini, M. R. (2011) · Expert Review of Hematology · doi:10.1586/ehm.11.29 · Cited by 161
Extracellular Electron Transfer Powers Enterococcus faecalis Biofilm Metabolism
Keogh, D., Lam, L. N., Doyle, L. E., Matysik, A. S., Pavagadhi, S., Umashankar, S., Low, P. M., Dale, J. L., Song, Y., Ng, S. P., et al. (2018) · mBio · doi:10.1128/mbio.00626-17 · Cited by 138
Anemia in the pediatric patient
Gallagher, P. G. (2022) · Blood · doi:10.1182/blood.2020006479 · Cited by 205
A More Universal Approach to Comprehensive Analysis of Thalassemia Alleles (CATSA)
Liang, Q., Gu, W., Chen, P., Li, Y., Liu, Y., Tian, M., Zhou, Q., Qi, H., Zhang, Y., He, J., et al. (2021) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.06.008 · Cited by 114
Cai, L., Bai, H., Mahairaki, V., Gao, Y., He, C., Wen, Y., Jin, Y.-C., Wang, Y., Pan, R. L., Qasba, A., et al. (2017) · Stem Cells Translational Medicine · doi:10.1002/sctm.17-0066 · Cited by 111
Genomic history of the Sardinian population
Chiang, C. W. K., Marcus, J. H., Sidore, C., Biddanda, A., Al-Asadi, H., Żołędziewska, M., Pitzalis, M., Busonero, F., Maschio, A., Pistis, G., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0215-8 · Cited by 116
Cationic Polymer‐Mediated CRISPR/Cas9 Plasmid Delivery for Genome Editing
Zhang, Z., Wan, T. Y., Chen, Y., Chen, Y., Sun, H., Cao, T., Songyang, Z., Tang, G., Wu, C., Yuan, P., et al. (2018) · Macromolecular Rapid Communications · doi:10.1002/marc.201800068 · Cited by 113
The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Inherited Diseases
Abdelnour, S. A., Xie, L., Hassanin, A. A., Zuo, E., & Lu, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.699597 · Cited by 143
Long-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: the HGB-205 trial
Magrin, E., Semeraro, M., Hebert, N., Joseph, L., Magnani, A., Chalumeau, A., Gabrion, A., Roudaut, C., Marouene, J., Lefrère, F., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01650-w · Cited by 118
Parums, D. V. (2024) · Medical Science Monitor · doi:10.12659/msm.944204 · Cited by 109
Niu, X., He, W., Song, B., Ou, Z., Fan, D., Chen, Y., Fan, Y., & Sun, X. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.719237 · Cited by 99
Population Screening for Hemoglobinopathies
Goonasekera, H. W. W., Paththinige, C. S., & Dissanayake, V. H. W. (2018) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-091416-035451 · Cited by 107
Xu, L., Mao, A., Liu, H., Gui, B., Choy, K. W., Huang, H., Yu, Q., Zhang, X., Chen, M., Lin, N., et al. (2020) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2020.05.004 · Cited by 92
Pregnancy in women with thalassemia: challenges and solutions
Tsironi, M., Petrakos, G., & Andriopoulos, P. (2016) · International Journal of Women s Health · doi:10.2147/ijwh.s89308 · Cited by 96
Pavani, G., Fabiano, A., Laurent, M., Amor, F., Cantelli, E., Chalumeau, A., Maule, G., Tachtsidi, A., Concordet, J., Cereseto, A., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020001996 · Cited by 104
Hypercoagulability in β-thalassemia: a status quo
Cappellini, M. D., Poggiali, E., Taher, A. T., & Musallam, K. M. (2012) · Expert Review of Hematology · doi:10.1586/ehm.12.42 · Cited by 85
Molecular characterization of thalassemia and hemoglobinopathy in Southeastern China
Huang, H., Xu, L., Chen, M., Lin, N., Xue, H., Chen, L., Wang, Y., He, D., Zhang, M., & Lin, Y. (2019) · Scientific Reports · doi:10.1038/s41598-019-40089-5 · Cited by 80
Thalassemia: Pathophysiology, Diagnosis, and Advances in Treatment
Sadiq, I. Z., Abubakar, F. S., Usman, H. S., Abdullahi, A. D., Ibrahim, B., Katsayal, B. S., Ibrahim, M., & Hassan, H. A. (2024) · Thalassemia Reports · doi:10.3390/thalassrep14040010 · Cited by 102
Leung, T. Y., & Lao, T. T.-H. (2011) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2011.10.009 · Cited by 77
Oral ferroportin inhibitor VIT‐2763: First‐in‐human, phase 1 study in healthy volunteers
Richard, F., van Lier, J. J., Roubert, B., Haboubi, T., Göhring, U., & Dürrenberger, F. (2019) · American Journal of Hematology · doi:10.1002/ajh.25670 · Cited by 81
β-Thalassemia and ocular implications: a systematic review
Liaska, A. P., Petrou, P., Georgakopoulos, C. D., Diamanti, R., Papaconstantinou, D., Kanakis, M. G., & Georgalas, I. (2016) · BMC Ophthalmology · doi:10.1186/s12886-016-0285-2 · Cited by 70
Metal Ion Signaling in Biomedicine
Rodriguez, R., Müller, S., Colombeau, L., Solier, S., Sindikubwabo, F., & Cañeque, T. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00577 · Cited by 76
A new index to discriminate between iron deficiency anemia and thalassemia trait
Matos, J. F., Dusse, L. M. S., Borges, K. B. G., de Castro, R. L. V., Coura‐Vital, W., & Ferriani, M. D. G. C. (2016) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.1016/j.bjhh.2016.05.011 · Cited by 66
Wattanapanitch, M., Damkham, N., Potirat, P., Trakarnsanga, K., Janan, M., U‐pratya, Y., Kheolamai, P., Klincumhom, N., & Issaragrisil, S. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-0779-3 · Cited by 69
Neurological complications of beta-thalassemia
Nemtsas, P., Arnaoutoglou, M., Perifanis, V., Koutsouraki, E., & Orologas, A. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2378-z · Cited by 64
Hsp90 chaperones hemoglobin maturation in erythroid and nonerythroid cells
Ghosh, A., Garee, G., Sweeny, E. A., Nakamura, Y., & Stuehr, D. J. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717993115 · Cited by 62
Natural Antioxidants in Anemia Treatment
Cotoraci, C. A., Ciceu, A., Sasu, A., & Hermenean, A. O. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041883 · Cited by 77
Molecular basis and diagnosis of thalassemia
Lee, J., Cho, S. I., Park, S. S., & Seong, M. (2021) · Blood Research · doi:10.5045/br.2021.2020332 · Cited by 61
Current trends of clinical trials involving CRISPR/Cas systems
Zhang, S., Wang, Y., Mao, D., Wang, Y., Zhang, H., Pan, Y., Wang, Y., Teng, S., & Huang, P. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1292452 · Cited by 70
Dybaś, J., Alcicek, F. C., Wajda, A., Kaczmarska, M. J., Zimna, A., Bułat, K., Blat, A., Степаненко, Т., Mohaissen, T., Szczęsny-Małysiak, E., et al. (2021) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2021.116481 · Cited by 60
Xiong, L., Barrett, A. N., Hua, R., Tan, T. Z., Ho, S. S. Y., Chan, J. K. Y., Zhong, M., & Choolani, M. A. (2014) · Prenatal Diagnosis · doi:10.1002/pd.4536 · Cited by 57
Chen, S.-H., Yang, W., Fan, Y., Stocco, G., Crews, K. R., Yang, J. J. J., Paugh, S. W., Pui, C.-H., Evans, W. E., & Relling, M. V. (2010) · Leukemia · doi:10.1038/leu.2010.256 · Cited by 59
Mohammadi, E., Tamaddoni, A., Qujeq, D., Nasseri, E., Zayeri, F., Zand, H., Gholami, M., & Mir, S. M. (2018) · Phytotherapy Research · doi:10.1002/ptr.6118 · Cited by 57
Gene correction of HBB mutations in CD34+ hematopoietic stem cells using Cas9 mRNA and ssODN donors
Antony, J. S., Latifi, N., Haque, A. K. M. A., Lamsfus‐Calle, A., Daniel-Moreno, A., Graeter, S., Baskaran, P., Weinmann, P., Mezger, M., Handgretinger, R., et al. (2018) · Molecular and Cellular Pediatrics · doi:10.1186/s40348-018-0086-1 · Cited by 58
Özdemir, Z. C., Koç, A., Ayçiçek, A., & Koçyiğit, A. (2014) · Hemoglobin · doi:10.3109/03630269.2014.951890 · Cited by 55
New insights into transfusion-related iron toxicity: Implications for the oncologist
Porter, J. B., de Witte, T., Cappellini, M. D., & Gattermann, N. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.11.017 · Cited by 59
Epidemiology of Thalassemia in Gulf Cooperation Council Countries: A Systematic Review
Abu-Shaheen, A. K., Heena, H., Nofal, A., Abdelmoety, D., Al-Matary, A., Alsheef, M. A., & AlFayyad, I. (2020) · BioMed Research International · doi:10.1155/2020/1509501 · Cited by 54
Kountouris, P., Kousiappa, I., Papasavva, T., Christopoulos, G., Pavlou, E., Petrou, M., Feleki, X., Karitzie, E., Phylactides, M., Fanis, P., et al. (2016) · Scientific Reports · doi:10.1038/srep26371 · Cited by 50
Non-invasive prenatal diagnosis of thalassemias using maternal plasma cell free DNA
Hudecova, I., & Chiu, R. W. K. (2016) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2016.10.016 · Cited by 52
Genome editing in large animal models
Maynard, L. H., Humbert, O., Peterson, C. W., & Kiem, H. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.026 · Cited by 51
Nanovesicle-Mediated Delivery Systems for CRISPR/Cas Genome Editing
Kim, D., Le, Q., Wu, Y., Park, J.-W., & Oh, Y. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121233 · Cited by 52
Barteselli, G., Dell’Arti, L., Finger, R. P., Issa, P. C., Marcon, A., Vezzola, D., Mapelli, C., Cassinerio, E., Cappellini, M. D., Ratiglia, R., et al. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.10.016 · Cited by 48
AlAgha, A. S., Faris, H., HAMMO, B. H., & Al-Zoubi, A. M. (2018) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2018.04.009 · Cited by 55
Thalassemia: A Review of the Challenges to the Families and Caregivers
Yousuf, R., Akter, S., Wasek, S. M., Sinha, S., Ahmad, R., & Haque, M. (2022) · Cureus · doi:10.7759/cureus.32491 · Cited by 43
Reddy, P. S., Locke, M., & Badawy, S. M. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2028894 · Cited by 51
Induction and application of human naive pluripotency
Zhou, J., Hu, J., Wang, Y., & Gao, S. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112379 · Cited by 45
Thalassaemia screening and confirmation of carriers in parents
Barrett, A. N., Ramasamy, S., & Choolani, M. A. (2016) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2016.10.015 · Cited by 43
Trichothiodystrophy causative TFIIEβ mutation affects transcription in highly differentiated tissue
Theil, A. F., Mandemaker, I. K., van den Akker, E., Swagemakers, S. M. A., Raams, A., Wüst, T., Marteijn, J. A. F., Giltay, J. C., Rm, C., Moog, U., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx351 · Cited by 40
A Melting Curve Analysis–Based PCR Assay for One-Step Genotyping of β-Thalassemia Mutations
Xiong, F., Huang, Q., Chen, X., Zhou, Y., Zhang, X., Cai, R., Chen, Y., Xie, J., Feng, S.-W., Wei, X., et al. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2011.03.005 · Cited by 42
Agouti, I., Cointe, S., Robert, S., Judicone, C., Loundou, A., Driss, F., Brisson, A. R., Steschenko, D., Rosé, C., Pondarré, C., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13609 · Cited by 41
Orbe, R. D., Arrizabalaga, B., de la Hoz, A. B., García‐Orad, Á., Tejada, M., García‐Ruiz, J. C., Fidalgo, T., Bento, C., Manco, L., & Ribeiro, L. (2016) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12551 · Cited by 41
Hydroxyurea for nontransfusion-dependent β-thalassemia: A systematic review and meta-analysis
Algiraigri, A. H., Wright, N. A. M., Paolucci, E. O., & Kassam, A. (2017) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2017.02.002 · Cited by 43
Nasseri, E., Mohammadi, E., Tamaddoni, A., Qujeq, D., Zayeri, F., & Zand, H. (2017) · Annals of Nutrition and Metabolism · doi:10.1159/000479634 · Cited by 42
Thalassemia in the United Arab Emirates: Why it can be prevented but not eradicated
Kim, S., & Tridane, A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170485 · Cited by 42
Circulatory, Reticuloendothelial, and Hematopoietic Disorders
Grauer, A. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-809738-0.00014-4 · Cited by 42
Autologous gene therapy for hemoglobinopathies: From bench to patient’s bedside
Locatelli, F., Cavazzana, M., Frangoul, H., de la Fuente, J., Algeri, M., & Meisel, R. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.03.005 · Cited by 48
Multiplex precise base editing in cynomolgus monkeys
Zhang, W., Aida, T., del Rosario, R. C. H., Wilde, J. J., Ding, C., Zhang, X., Baloch, Z., Huang, Y., Tang, Y., Li, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16173-0 · Cited by 46
The Evidence-Based Evaluation of Iron Deficiency Anemia
Hempel, E. V., & Bollard, E. R. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.04.015 · Cited by 47
Xiong, L., Barrett, A. N., Hua, R., Ho, S., Jun, L., Chan, K., Mei, Z., & Choolani, M. A. (2017) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.15045 · Cited by 38
Molecular genetics of β-thalassemia: A narrative review.
Jaing, T., Chang, T., Chen, S., Lin, C., Wen, Y., & Chiu, C.-C. (2021) · PubMed Central · doi:10.1097/md.0000000000027522 · Cited by 51
Predicting Thalassemia Using Feature Selection Techniques: A Comparative Analysis
Saleem, M., Aslam, W., Lali, M. I. U., Rauf, H. T., & Nasr, E. A. (2023) · Diagnostics · doi:10.3390/diagnostics13223441 · Cited by 43
Between hope and reality: treatment of genetic diseases through nucleic acid-based drugs
Baylot, V., Le, T. K., Taïeb, D., Rocchi, P., & Colleaux, L. (2024) · Communications Biology · doi:10.1038/s42003-024-06121-9 · Cited by 47
Retinal abnormalities in β-thalassemia major
Bhoiwala, D. L., & Dunaief, J. L. (2015) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2015.08.005 · Cited by 40
Soni, S. (2020) · American Journal of Hematology · doi:10.1002/ajh.25909 · Cited by 42
Borderline HbA2 levels: Dilemma in diagnosis of beta-thalassemia carriers
Colaco, S., & Nadkarni, A. H. (2021) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2021.108387 · Cited by 43
Aydınok, Y. (2012) · Hematology · doi:10.1179/102453312x13336169155295 · Cited by 37
Modifier genes in Mendelian disorders: the example of hemoglobin disorders
Sankaran, V. G., Lettre, G., Orkin, S. H., & Hirschhorn, J. N. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05821.x · Cited by 40
Traivaree, C., Boonyawat, B., & Monsereenusorn, C. (2014) · The Application of Clinical Genetics · doi:10.2147/tacg.s73058 · Cited by 36
Scherrer, K. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.09.011 · Cited by 39
CRISPR technology for genome editing
Bhattacharjee, G., Mani, I., Gohil, N., Khambhati, K., Braddick, D., Panchasara, H., & Singh, V. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-819178-1.00007-1 · Cited by 38
Metabolomics in genetic testing
Troisi, J., Cavallo, P., Colucci, A., Pierri, L., Scala, G., Symes, S. J. K., Jones, C., & Richards, S. M. (2020) · Advances in clinical chemistry · doi:10.1016/bs.acc.2019.07.009 · Cited by 41
Ocular abnormalities in multi-transfused beta-thalassemia patients
Heydarian, S., Jafari, R., Karami, H., Shektaei, M., Dailami, K. N., Amiri, A. A., Rezaee, M. R. S., & Far, A. F. (2015) · Indian Journal of Ophthalmology · doi:10.4103/0301-4738.170986 · Cited by 35
Human induced pluripotent stem cells for monogenic disease modelling and therapy
Spitalieri, P., Talarico, V. R., Murdocca, M., Novelli, G., & Sangiuolo, F. C. (2016) · World Journal of Stem Cells · doi:10.4252/wjsc.v8.i4.118 · Cited by 38
Cellular Electrophysiology of Iron-Overloaded Cardiomyocytes
Siri‐Angkul, N., Xie, L., Chattipakorn, S. C., & Chattipakorn, N. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01615 · Cited by 32
Romanello, K. S., Teixeira, K. K. L., da Silva, J. P. M. D. O., Nagamatsu, S. T., Bezerra, M., Domingos, I. F., Pereira‐Martins, D. A., Araujo, A. S., Lanaro, C., Breyer, C. A., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0208316 · Cited by 34
The Genetic Architecture of High Bone Mass
Gregson, C. L., & Duncan, E. L. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.595653 · Cited by 35
Epigenetic Insights and Potential Modifiers as Therapeutic Targets in β–Thalassemia
Zakaria, N. A., Islam, M. A., Abdullah, W. Z., Bahar, R., Yusoff, A. A. M., Wahab, R. A., Shamsuddin, S., & Johan, M. F. (2021) · Biomolecules · doi:10.3390/biom11050755 · Cited by 37
Mirlohi, M. S., Yaghooti, H., Shirali, S., Asnafi, A. A., & Olapour, S. (2018) · Annals of Hematology · doi:10.1007/s00277-017-3223-3 · Cited by 32
Borgatti, M., Altamura, E., Salvatori, F., D’Aversa, E., & Altamura, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020289 · Cited by 33
Al‐Hakeim, H. K., Najm, A. H., Al-Dujaili, A. H., & Maes, M. H. J. (2020) · Neurotoxicity Research · doi:10.1007/s12640-020-00193-1 · Cited by 37
CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia
Zeng, S., Lei, S.-Y., Qu, C., Wang, Y., Teng, S., & Huang, P. C. (2023) · Human Genetics · doi:10.1007/s00439-023-02610-9 · Cited by 37
Rescue of wild-type E-cadherin expression from nonsense-mutated cancer cells by a suppressor-tRNA
Bordeira–Carriço, R., Ferreira, D. A., Mateus, D. D., Pinheiro, H. C., Pêgo, A. P., Santos, M. A. S., & Oliveíra, C. (2014) · European Journal of Human Genetics · doi:10.1038/ejhg.2013.292 · Cited by 30
Molecular basis and prenatal diagnosis of β‐thalassemia among Balouch population in Iran
Miri‐Moghaddam, E., Zadeh–Vakili, A., Rouhani, Z., Naderi, M., Eshghi, P., & Feizabad, A. K. (2011) · Prenatal Diagnosis · doi:10.1002/pd.2767 · Cited by 30
Metadata
- Authors
- Cao, A., & Galanello, R.
- Affiliations
- National Research Council (IT)
- University of Cagliari (IT)
- Corresponding author
- Cao, Antonio
- Venue
- Genetics in Medicine
- Publisher
- Elsevier BV
- Published
- 2010-02
- Volume
- 12
- Issue
- 2
- Pages
- 61-76
- ISSN
- 1098-3600 (ISSN-L)
- OpenAlex
- W4210970197
- Cited by
- 722
- References
- 4
- Citations by year
- 2026: 43 · 2025: 48 · 2024: 63 · 2023: 61 · 2022: 60 · 2021: 66 · 2020: 69 · 2019: 64 · 2018: 48 · 2017: 58 · 2016: 52 · 2015: 24 · 2014: 14 · 2013: 20 · 2012: 15
- FWCI
- 1.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 4370 d)
- Locations
- Genetics in Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Keywords
- beta-thalassemia, beta-globin gene, HBB mutations, thalassemia major, thalassemia intermedia, transfusion-dependent anemia, iron chelation therapy, bone marrow transplantation, fetal hemoglobin induction, genetic counseling, prenatal diagnosis, chromosome 11
- MeSH terms
- Female, Multigene Family, Genetic Testing, Globins, Genetic Carrier Screening, Humans, Pregnancy, Prenatal Diagnosis, Bone Marrow Transplantation, beta-Thalassemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.